{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:28:38Z","timestamp":1791347318749,"version":"4.3.1"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2014,3,7]],"date-time":"2014-03-07T00:00:00Z","timestamp":1394150400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0090350","type":"journal-article","created":{"date-parts":[[2014,3,7]],"date-time":"2014-03-07T21:18:04Z","timestamp":1394227084000},"page":"e90350","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["Plasma Concentrations, Efficacy and Safety of Efavirenz in HIV-Infected Adults Treated for Tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA Trial)"],"prefix":"10.1371","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct01300481","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Laurence","family":"Borand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoann","family":"Madec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Laureillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monidarin","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Marcy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phearavin","family":"Pheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narom","family":"Prak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chindamony","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khemarin Kim","family":"Lak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanroeun","family":"Hak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bunnet","family":"Dim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Nerrienet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Fontanet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thim","family":"Sok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne E.","family":"Goldfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois-Xavier","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Taburet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,3,7]]},"reference":[{"key":"ref1","first-page":"115","article-title":"Antiretroviral therapy in AIDS patients with tuberculosis","volume":"8","author":"S Moreno","year":"2006","journal-title":"AIDS Rev"},{"key":"ref2","unstructured":"WHO (2013) Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach."},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1086\/599115","article-title":"Efavirenz and nevirapine interactions with rifampicin: resolving the dilemmas?","volume":"48","author":"UG Lalloo","year":"2009","journal-title":"Clin Infect Dis"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00228-011-1166-5","article-title":"The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis","volume":"68","author":"TN Gengiah","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/jama.2012.7961","article-title":"Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel","volume":"308","author":"MA Thompson","year":"2012","journal-title":"JAMA"},{"key":"ref6","unstructured":"FDA (2012) Sustiva labeling update\/dosing adjustment with rifampin (Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.fda.gov\/ForConsumers\/ByAudience\/ForPatientAdvocates\/HIVandAIDSActivities\/ucm294476.htm\" xlink:type=\"simple\">http:\/\/www.fda.gov\/ForConsumers\/ByAudience\/ForPatientAdvocates\/HIVandAIDSActivities\/ucm294476.htm<\/ext-link>. Accessed 2014 February 5)."},{"key":"ref7","unstructured":"BHIVA (2012) BHIVA guidelines for the treatment of HIV-1 positive adults with antiretroviral therapy 2012."},{"key":"ref8","unstructured":"Morlat P (2013) Prise en charge m\u00e9dicale des personnes vivant avec le VIH - Recommandations du groupe d&apos;experts - Rapport 2013. (Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.sante.gouv.fr\/IMG\/pdf\/Rapport_Morlat_2013_Mise_en_ligne.pdf\" xlink:type=\"simple\">http:\/\/www.sante.gouv.fr\/IMG\/pdf\/Rapport_Morlat_2013_Mise_en_ligne.pdf<\/ext-link>. Accessed 2014 February 5)."},{"key":"ref9","unstructured":"CDC (2012) Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents."},{"key":"ref10","unstructured":"WHO (2010) Antiretroviral Therapy for HIV infection in Adults and Adolescents. Recommendations for a public health approach. 2010 Revision. World Health Organization."},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa1013911","article-title":"Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis","volume":"365","author":"FX Blanc","year":"2011","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1517\/17425255.4.7.965","article-title":"Efavirenz\u2014still first-line king?","volume":"4","author":"BM Best","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00002030-200101050-00011","article-title":"Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients","volume":"15","author":"C Marzolini","year":"2001","journal-title":"Aids"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0378-4347(99)00573-3","article-title":"Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction","volume":"740","author":"C Marzolini","year":"2000","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"ref16","unstructured":"AIDS (2009) Division of AIDS Table for grading the severity of the adults and pediatric adverse events version 1.0, December, 2004; Clarification August 2009."},{"key":"ref17","unstructured":"BMS (2013) SUSTIVA Package Insert (Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/packageinserts.bms.com\/pi\/pi_sustiva.pdf\" xlink:type=\"simple\">http:\/\/packageinserts.bms.com\/pi\/pi_sustiva.pdf<\/ext-link>. Accessed 2014 February 5)."},{"key":"ref18","first-page":"2391","article-title":"Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study","volume":"18","author":"DW Haas","year":"2004","journal-title":"Aids"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/QAI.0b013e31819c3376","article-title":"Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women","volume":"50","author":"M Gandhi","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Luetkemeyer AF, Rosenkranz SL, Lu D, Marzan F, Ive P, <etal>et al<\/etal>.. (2013) Relationship Between Weight, Efavirenz Exposure, and Virologic Suppression in HIV-Infected Patients on Rifampin-Based Tuberculosis Treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. Clin Infect Dis.","DOI":"10.1093\/cid\/cit246"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1097\/01.aids.0000183630.27665.30","article-title":"Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin","volume":"19","author":"W Manosuthi","year":"2005","journal-title":"Aids"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1124\/jpet.103.049601","article-title":"The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV\/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity","volume":"306","author":"BA Ward","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/infdis\/jis508","article-title":"A single-nucleotide polymorphism in CYP2B6 leads to &gt;3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women","volume":"206","author":"M Gandhi","year":"2012","journal-title":"J Infect Dis"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01213011-200501000-00001","article-title":"Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients","volume":"15","author":"M Rotger","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1086\/599114","article-title":"A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study","volume":"48","author":"W Manosuthi","year":"2009","journal-title":"Clin Infect Dis"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1742-6405-7-8","article-title":"Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV\/TB co-infected Thai adults","volume":"7","author":"S Uttayamakul","year":"2010","journal-title":"AIDS Res Ther"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2165\/00003088-200241090-00004","article-title":"Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis","volume":"41","author":"LF Lopez-Cortes","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1128\/AAC.00980-10","article-title":"Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteers","volume":"55","author":"A Kwara","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/135965350801300507","article-title":"Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication","volume":"13","author":"W Stohr","year":"2008","journal-title":"Antivir Ther"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1128\/AAC.00899-08","article-title":"CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India","volume":"53","author":"G Ramachandran","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1128\/AAC.05452-11","article-title":"Presence of lamivudine or emtricitabine is associated with reduced emergence of nonnucleoside reverse transcriptase inhibitor mutations in an efavirenz-based intermittent antiretroviral treatment regimen","volume":"56","author":"S Trancart","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1590\/S1413-86702004000300004","article-title":"Efficacy and safety of Efavirenz in HIV patients on Rifampin for tuberculosis","volume":"8","author":"DB Pedral-Sampaio","year":"2004","journal-title":"Braz J Infect Dis"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/jac\/dkl399","article-title":"Administration of efavirenz (600 mg\/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV","volume":"58","author":"G Friedland","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1097\/01.qai.0000135956.96166.f0","article-title":"Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive patients in India who are coinfected with tuberculosis and HIV-1","volume":"37","author":"A Patel","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1086\/427337","article-title":"Therapeutic response of HIV-1 subtype C in African patients coinfected with either Mycobacterium tuberculosis or human herpesvirus-8","volume":"191","author":"E Cassol","year":"2005","journal-title":"J Infect Dis"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3851\/IMP1780","article-title":"Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?","volume":"16","author":"C Orrell","year":"2011","journal-title":"Antivir Ther"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1001\/jama.300.5.530","article-title":"Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy","volume":"300","author":"A Boulle","year":"2008","journal-title":"Jama"},{"key":"ref38","first-page":"360","article-title":"Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana","volume":"13","author":"LK Shipton","year":"2009","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1365-2125.2005.02536.x","article-title":"Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism","volume":"61","author":"D Burger","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1086\/383031","article-title":"Anemia in HIV infection: clinical impact and evidence-based management strategies","volume":"38","author":"PA Volberding","year":"2004","journal-title":"Clin Infect Dis"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/01.qai.0000147523.41993.47","article-title":"Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence","volume":"38","author":"CR Fumaz","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"714","DOI":"10.7326\/0003-4819-143-10-200511150-00008","article-title":"Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals","volume":"143","author":"DB Clifford","year":"2005","journal-title":"Ann Intern Med"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"149","DOI":"10.7326\/0003-4819-151-3-200908040-00127","article-title":"Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial","volume":"151","author":"A Gutierrez-Valencia","year":"2009","journal-title":"Ann Intern Med"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Shubber Z, Calmy A, Andrieux-Meyer I, Vitoria M, Renaud-Thery F, <etal>et al<\/etal>.. (2013) Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS.","DOI":"10.1097\/QAD.0b013e32835f1db0"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1086\/655470","article-title":"Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study","volume":"202","author":"HJ Ribaudo","year":"2010","journal-title":"J Infect Dis"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/00126334-200112010-00015","article-title":"Higher efavirenz plasma levels correlate with development of insomnia","volume":"28","author":"M Nunez","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1097\/01.aids.0000183519.45137.a6","article-title":"Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all","volume":"19","author":"P Brennan-Benson","year":"2005","journal-title":"Aids"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1517\/14656566.8.6.851","article-title":"Efavirenz: a review","volume":"8","author":"SM Vrouenraets","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/135965350901400116","article-title":"Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA study","volume":"14","author":"M van Luin","year":"2009","journal-title":"Antivir Ther"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1177\/135965350501000404","article-title":"Are adverse events of nevirapine and efavirenz related to plasma concentrations?","volume":"10","author":"BS Kappelhoff","year":"2005","journal-title":"Antivir Ther"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0090350","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T01:19:21Z","timestamp":1689038361000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0090350"}},"subtitle":[],"editor":[{"given":"Javier R.","family":"Lama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,3,7]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,3,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0090350","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,7]]}}}